The global digital pills market size was valued at USD 5.44 billion in 2025 and is projected to grow from USD 6.26 billion in 2026 to USD 19.26 billion by 2034, registering a CAGR of 15.08% during the forecast period from 2026 to 2034. North America dominated the digital pills market with a market share of 42.5% in 2025.
The rising incidence of schizophrenia and the increasing need for immediate treatment of manic episodes globally are expected to propel the market. Moreover, the market growth is expected to be positively influenced by the increasing investments in research and development of smart pills. This can be attributed to the rising number of FDA approvals for digital pills.
A medication that uses a small, edible sensor or other digital technology to track different aspects of the patient's health and medication usage is called a "digital pill." The objectives include enhancing medication adherence and giving medical professionals up-to-date information on a patient's reaction to treatment. It captures three-dimensional high-resolution images, which helps with real-time reminders related to the dosage of the pills. This pill can travel safely through the body and communicate with external devices.
Download a Free Sample To learn more about this report,
AI-Assisted Capsule Interpretation Is Reducing the Manual Burden of Image Review
The large volume of images generated during capsule endoscopy is encouraging the use of AI-assisted interpretation tools to identify potential findings and reduce manual review time. This transition allows software to support clinicians by prioritizing relevant images while keeping final assessment with the physician, as reflected in the FDA-cleared Deep Capsule system for adult patients undergoing small-bowel capsule endoscopy for suspected bleeding. In March 2026, the FDA cleared Deep Capsule under 510(k) K250655 specifically to help decrease capsule-image review time, while requiring clinicians to review the complete video and retain responsibility for clinical decisions.
Digital Pills Are Expanding From Medication Adherence Into Continuous Gastrointestinal Monitoring
The integration of physiological sensors into ingestible capsules is shifting digital pills beyond medication adherence toward direct gastrointestinal monitoring. This transition enables a single capsule to collect measurements such as pressure, pH, and temperature across different sections of the gastrointestinal tract, supporting assessment of motility and transit. In May 2025, the FDA cleared AnX Robotica's MotiliCap GI Monitoring System as a Class II gastrointestinal motility monitoring device, demonstrating the movement of sensor-based digital pills into regulated clinical monitoring applications.
Digital Medicine Partnerships and Clinical Trial Adherence Needs Drive Market Growth
Pharmaceutical companies are forming digital-health partnerships that connect medicines with technologies for objective medication-use monitoring. ClinicalTrials.gov records a PrEP study involving 30 participants in which a digital pill transmitted direct evidence of Truvada ingestion to a wearable reader, smartphone, and cloud server. Such applications give drug manufacturers and healthcare providers a way to combine therapy with adherence monitoring and patient-support services. Partnership models around connected medicines therefore expand the commercial use of digital pills beyond conventional drug delivery.
Clinical trials require objective medication-use data because missed doses can make treatment efficacy harder to evaluate accurately. An official ClinicalTrials.gov study used a digital pill to measure adherence to antiretroviral therapy, with 54 participants included in the digital-pill analysis and adherence tracked over 16 weeks. The system directly recorded the type, dose, date, and time of oral medication ingestion, providing researchers with data beyond self-reported adherence. Applications such as HIV treatment studies demonstrate the value of digital pills for adherence measurement in clinical research.
High Digital Pill Costs and Data Privacy Risks Restrain Market Expansion
High costs of digital pills increase the financial burden associated with ingestible sensors, data platforms, and supporting monitoring systems. Limited affordability and reimbursement coverage can discourage healthcare providers and patients from adopting these technologies, restricting wider market penetration.
Data privacy and security concerns increase the need for secure transmission, storage, and management of sensitive patient and medication data. Additional cybersecurity controls and compliance requirements can raise implementation complexity, which can delay deployment and limit adoption of digital pills.
Digital Pills Create Opportunities in Targeted Drug Delivery and Clinical Research Data Services
Pharmaceutical companies, drug-delivery specialists, and medical-device developers can use digital pills for controlled and site-specific drug release. Companies such as Medtronic can generate revenue through smart drug-delivery platforms, device integration, licensing, and pharmaceutical partnerships. Clinical research organizations, pharmaceutical companies, and digital-health providers can use digital pills to capture objective treatment and physiological data during clinical studies. Companies such as etectRx can create revenue through digital-pill platforms, clinical trial services, data solutions, and technology licensing.
Clinical Workflow Integration and Abilify MyCite Commercialization Challenges
Digital pills must fit into existing prescribing, dispensing, administration, and patient-monitoring workflows across healthcare settings. Differences in clinical processes can increase implementation complexity and make it difficult for providers to scale adoption across multiple facilities.
Otsuka discontinued commercialization of Abilify MyCite in 2025, citing limited commercial uptake and a decision to focus resources on other opportunities. The experience highlights the difficulty of translating an approved digital-pill platform into sustained commercial adoption, even when the underlying technology is available.
Tracking Ingestion in Schizophrenia Patients is the dominant segment, accounting for 46.8% of the market share. Its leading position is supported by the use of digital pills to monitor medication ingestion and adherence among patients requiring long-term treatment. Tracking Ingestion in Bipolar Patients represents another important application, while Adjunctive Treatment of MDD in Adults supports medication monitoring in major depressive disorder treatment.
Adjunctive Treatment of MDD in Adults is the fastest-growing segment, registering an 11.8% CAGR 2026-2034. Its growth is supported by the use of digital pills as part of medication management for adults receiving treatment for major depressive disorder, while Tracking Ingestion in Bipolar Patients continues to support adherence monitoring among bipolar patients.
Request Customizationto receive a tailored report.
Hospitals are the dominant segment, accounting for 49.6% of the market share in 2025. Their leading position is supported by the use of digital pills within structured clinical settings for medication monitoring and patient management. Clinics represent another important end-user group, supporting digital pill use across outpatient treatment and medication management.
Home Care Settings are the fastest-growing segment, registering a 12.4% CAGR. Its growth is supported by the use of digital pills for medication monitoring outside institutional healthcare environments, while Hospitals and Clinics continue to account for substantial adoption across supervised and outpatient care settings.
Speak to an Analystto discuss market opportunities.
North America dominated the global digital pills market with a 42.5% share. The region benefits from advanced healthcare infrastructure, strong adoption of digital health technologies, and established pharmaceutical and healthcare technology ecosystems supporting the use of digital pills for medication adherence, gastrointestinal monitoring, and diagnostic applications.
The U.S. digital pills market is supported by the U.S. Office of the National Coordinator for Health IT’s 2024–2030 Federal Health IT Strategic Plan, which is intended to advance access, exchange, and use of electronic health information through 2030. The Canada digital pills market is supported by Canada’s Pan-Canadian health-data vision, which targets 2030 for all people in Canada to benefit from a fully integrated and continuously optimized learning health system, supporting wider use of interoperable digital health and patient-monitoring technologies.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe is the fastest-growing region in the digital pills market, with a projected CAGR of 12.6% during the forecast period. Expanding digital healthcare adoption, increasing use of remote patient monitoring, and greater integration of connected medical technologies into clinical care are supporting regional market growth.
The U.K. digital pills market is supported by the U.K. Government’s 10-Year Health Plan, which envisions that by 2035, intelligent wearables will monitor vital signs and biomarkers and support virtual wards as a standard model of care, strengthening the broader ecosystem for connected patient-monitoring technologies.
The Germany digital pills market benefits from the Federal Ministry of Health’s goal of developing the healthcare system into a digitally supported ecosystem by 2030, while its digitalization strategy targets more than 20 million insured people actively using the electronic patient record by 2030.
Asia Pacific accounted for an 18.7% share of the global digital pills market. Expanding healthcare infrastructure, growing adoption of digital health solutions, and increasing access to advanced diagnostic and medication-management technologies are creating a stronger foundation for digital pills across the region.
The Japan digital pills market is supported by the government’s national medical-DX program, which aims to improve the efficiency and quality of healthcare through digital transformation, while its 2025 Health and Medical Strategy continues to prioritize digital health as part of the country’s healthcare-development agenda.
The China digital pills market benefits from the Healthy China 2030 framework, which targets 2030 for interoperable health-information platforms across national, provincial, municipal, and county levels, with standardized electronic health records and remote medical services covering healthcare institutions from provincial to township levels. The India digital pills market is supported by the Ayushman Bharat Digital Mission, which has created 869.6 million ABHA accounts as of March 22, 2026, alongside 485,760 registered health facilities and 835,477 registered healthcare professionals, creating a large digital-health infrastructure base for connected medication and monitoring technologies.
The digital pills market is moderately fragmented, with competition comprising pharmaceutical companies, capsule endoscopy manufacturers, ingestible sensor developers, digital health companies, medical device manufacturers, and specialized drug-delivery technology providers. The leading players in the digital pills market are Proteus Digital Health Inc., Abbott, Novartis AG, CapsoVision, and iRhythm Technologies Inc., collectively accounting for approximately 22% of the global market.
Established players compete primarily on clinical validation, regulatory approvals, imaging and sensor accuracy, product reliability, integration with healthcare workflows, data analytics, intellectual property, and global distribution networks, while emerging players compete through AI-enabled interpretation, specialized ingestible technologies, compact device designs, cost-efficient solutions, flexible deployment models, and application-specific innovations.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Digital Pathology Market Size, Share, Growth, Forecast, 2034
Healthcare Supply Chain Market Size, Share, Growth, Analysis, 2034
Clinical Trial Management System Market Size, Share, Growth, 2034
Biohacking Market Size, Share, Growth, Analysis, Report, 2034
Bioinformatics Market Size, Share, Growth, Analysis, Report, 2034
E-Prescribing Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com